.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Baxter
Harvard Business School
US Department of Justice
Queensland Health
Federal Trade Commission
UBS
Mallinckrodt
Cerilliant
McKinsey

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,234,940

« Back to Dashboard

Details for Patent: 5,234,940

Title: Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
Abstract:A method of detecting and treating malignant and non-malignant tissue abnormalities and lesions of the skin; conjunctiva; respiratory, digestive and vaginal mucosa; endometrium and urothelium; and for ablating the endometrial tissue and treating body fluids containing suspended abnormal cells, and for treating cancers of the nervous system in which 5-aminolevulinic acid or precursor thereof is administered to the patient in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of of protoporphyrin IX in the abnormal cells, followed by exposure of the abnormal cells to light of photoactivating wavelengths.
Inventor(s): Kennedy; James C. (Kingston, CA), Pottier; Roy H. (Kingston, CA), Reid; Robert L. (Kingston, CA)
Assignee: Queen's University (Kingston, CA)
Filing Date:Apr 08, 1992
Application Number:07/865,151
Claims:1. A method for creating malignant and non-malignant cellular abnormalities of the endometrium and gonads in a patient comprising administering to said patient an effective amount of a precursor of protoporphyrin IX in the biosynthetic pathway for heme so as to induce synthesis of protoporphyrin IX in said abnormalities, and exposing said abnormalities to light within the photoactivating action spectrum of said protoporphyrin IX.

2. A method as claimed in claim 1 wherein said precursor of protoporphyrin IX is 5-aminolevulinic acid or a precursor thereof.

3. A method for treating dysfunctional uterine bleeding, endometriosis, iron deficiency anemia caused by excessive menstrual bleeding in a patient comprising administering to said patient a precursor of protoporphyrin IX in the biosynthetic pathway for heme, so as to induce synthesis of protoporphyrin IX in endometrial tissues in said patient, and exposing said tissues to light within the photoactivating spectrum of said protoporphyrin IX.

4. A method for sterilizing a patient comprising administering to said patient a precursor of protoporphyrin IX in the biosynthetic pathway for heme, so as to induce synthesis of protoporphyrin IX in endometrial tissues in said patient, and exposing said tissues to light within the photoactivating spectrum of said protoporphyrin IX.

5. A contraceptive method for female patients comprising administering to said patient a precursor of protoporphyrin IX in the biosynthetic pathway for heme, so as to induce synthesis of protoporphyrin IX in endometrial tissues in said patient, and exposing said tissues to light within the photoactivating spectrum of said protoporphyrin IX.

6. A method as claimed in claim 3 wherein said precursor is 5-aminolevulinic acid or precursor thereof.

7. A method as claimed in claim 4 wherein said precursor is 5-aminolevulinic acid or precursor thereof.

8. A method as claimed in claim 5 wherein said precursor is 5-aminolevulinic acid or precursor thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Novartis
QuintilesIMS
Daiichi Sankyo
Express Scripts
Covington
McKesson
Fish and Richardson
Chinese Patent Office
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot